Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2001 December;20(4) > International Angiology 2001 December;20(4):337-44





Rivista di Angiologia

Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899




International Angiology 2001 December;20(4):337-44


lingua: Inglese

Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication

Diamantopoulos E. J., Grigoriadou M., Ifanti G., Raptis S. A. *

From the 4th Depart­ment of Inter­nal Med­i­cine and * 2nd Depart­ment of Inter­nal Med­i­cine-Prop­a­edeu­tic of the Ath­ens Uni­ver­sity Med­i­cal ­School, “Evan­ge­lis­mos” State Gen­er­al Hos­pi­tal, Ath­ens, ­Greece


Back­ground. Chang­es in blood rhe­ol­o­gy have been ­described in dia­betes mel­lit­us. Buflom­e­dil, a vasoac­tive sub­stance with hemo­rhe­o­log­i­cal prop­er­ties, has been wide­ly used in the treat­ment of inter­mit­tent claud­i­ca­tion. The aim of this study was to eval­u­ate the ­effect of buflom­e­dil on clin­i­cal and hemo­rhe­o­log­i­cal param­e­ters in sub­jects with type 2 dia­betes and inter­mit­tent claud­i­ca­tion.
Meth­ods. Forty ­patients were ran­dom­ly ­assigned to oral buflom­e­dil or match­ing pla­ce­bo for six ­months in a dou­ble-blind man­ner. ­Initial and abso­lute walk­ing dis­tanc­es were ­assessed by a stan­dard tread­mill test­ing pro­to­col. Eryth­ro­cyte deform­abil­ity was esti­mat­ed with a whole blood fil­tra­tion tech­nique. ADP- and col­la­gen-­induced plate­let aggre­ga­tion was ­assessed with an aggre­ga­tion pro­fil­er. β-throm­bo­glob­u­lin and plate­let fac­tor-4 were meas­ured with radio­im­mu­noas­says. All tests were per­formed at base­line and after three and six ­months of treat­ment.
­Results. A sig­nif­i­cant ­increase in the mean ­initial (71%) and abso­lute (68%) walk­ing dis­tance was ­achieved only in the buflom­e­dil group. ADP- and col­la­gen-­induced plate­let aggre­ga­tion was sig­nif­i­cant­ly ­reduced in the buflom­e­dil group, while no sig­nif­i­cant chang­es in eryth­ro­cyte deform­abil­ity, β-throm­bo­glob­u­lin and plate­let fac­tor-4 lev­els were ­noticed. How­ev­er, β-throm­bo­glob­u­lin lev­els ­increased sig­nif­i­cant­ly in the pla­ce­bo group.
Con­clu­sions. These find­ings sug­gest the ther­a­peu­tic effi­ca­cy of buflom­e­dil in dia­bet­ic sub­jects with inter­mit­tent claud­i­ca­tion. The inhi­bi­tion of plate­let aggre­ga­tion and the influ­ence on plate­let activ­ity exert­ed by the drug could play an impor­tant role in its clin­i­cal ­effect and may be of value in the treat­ment of such ­patients.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail